THE PHARMACOKINETICS AND IMMUNOGENICITY OF USTEKINUMAB AND ADALIMUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE SEAVUE STUDY
Silvio Danese 1
Tony Ma 2
Omoniyi J. Adedokun 3
Christopher Gasink 3
Kamal Patel 4
James Izanec 4
Stephen B Hanauer 5
Ellen J. Scherl 6
1 Humanitas Clinical and Research Center, Humanitas University, Milan, Italy
2 Janssen Scientific Affairs, LLC, Horsham, United States
3 Janssen Research & Development, LLC, Spring House, United States
4 St. Georges University Hospitals, London, United Kingdom
5 Northwestern University Feinberg School of Medicine, Chicago, United States
6 New York Presbyterian Hospital Weill Cornell Medicine, New York, United States
Topic
IBD
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]